Precision Lung Cancer Logo

Day Two: Tuesday October 30, 2018

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Biomarkers & Companion Diagnostics

8:30

The relationship between PD-L1 and tumor mutational burden as independent biomarkers for lung cancer.

 

Rongze Olivia Lu

Senior Scientist III & Team Leader, Immuno-Oncology


AbbVie

9:00

Regulatory Innovation in Precision Medicine

Peggy Carter

Global Head Drug Regulatory Affairs

Novartis

9:30

ctDNA applications in EGFR mutant Lung Cancer

 

Juliann Chmielecki

Associate Director, Translational Science

 

AstraZeneca

10:00

NGS IVD Solutions for Lung Cancer


Donna Nichol

Associate Director, Diagnostic Strategy

 

PGDx

MORNING REFRESHMENTS & SPEED NETWORKING

10:30

11:00

The use of neoantigens for treatmernt and tracking of cancer patients

 

Mohamed Uduman

Senior Scientist, Bioinformatics

 

Agenus

11:30

The use of comprehensive liquid biopsy in clinical trials and clinical practice

 

Jessica Riley

Senior Director, BioPharma Business Development

 

Guardant Health

12:00

Advanced multiplexing reagents for measuring biomarker expression and cellular behavior in tissue for translational research and cohort studies

Dr. Sean Downing
Director of Customer Engagement

Ultivue

LUNCH & NETWORKING

12:10

PANEL DISCUSSION

1:00

Current advancements and challenges in Lung Cancer Drugs and Trial Designs - A focus on the Precision Medicine based approach.

 

Moderator: Kamala Maddali

Executive VP - Partnerships and Business Development


Cancer Genetics Inc.

Participants:

Jason Baum,
Executive Director, Precision Medicine Leader, Novartis

 

William Powell, Sr. Director, CDx Product Development,

Leica Biosystems

 

To Be Announced

 

To Be Announced

Novel Approaches

2:00

Discovering New Cancer Therapeutics by Targeting Stress Response and the NADome

 

Heike Keilhack

Vice President, Translational Sciences

 

Ribon Therapeutics

2:30

Precision targeted therapy with BLU-667for RET driven cancers

 

Erica Evans

Senior Director, Biology


Blueprint Medicines

AFTERNOON REFRESHMENTS & NETWORKING

3:00

3:30

CNS Metastases:  Challenges and novel approaches in dealing with this major driver of morbidity and mortality in lung cancer patients

 

Jeffrey Bacha

Co-Founder

DelMar Pharmaceuticals

4:00

Therapeutic Antibodies to novel embryonic targets in lung cancer

 

William Mike Schopperle

CEO and Founder

CureMeta

 

SUMMARY & CLOSE OF CONFERENCE

4:30

VIEW PREVIOUS DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2018 | All content produced by: neo-synth ltd.

DOWNLOAD GUIDE

Complete the form below to download the PDF